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Purpose: Dropped head syndrome is characterized by a gradual forward sagging of the
head due to the isolated weakness of the neck extensor muscles. The syndrome has a
relatively benign clinical course. To date, there have been no reports of dropped head
syndrome in epileptic patients.
Methods: Nine patients with intractable epilepsy (mean age, 33.6  9.91 years),
each presenting with apparent dropped head, were evaluated. The duration of the
drooping head symptom varied from 3 to 15 years (mean, 7.4  4.06 years), with a
slowly progressing weakness in most of the patients. In all of the patients, extensive
clinical, laboratory, electrophysiological, histopathological, and neuroimaging exam-
inations were performed.
Results: The weakness in all of the subjects was strictly limited to the cervical
paraspinal muscles. Laboratory studies produced normal results from all subjects.
EMG and muscle biopsy were normal or revealed subtle nonspecific myopathic changes
without inflammation in the cervical paraspinal muscles. Polymyographic investigation
revealed that none of the patients had convincing dystonic spasms of the anterior neck
muscles. No atrophy or fatty changes of the neck extensormuscleswere observed onCT
or MRI. In most of the patients (7/9), altered L-carnitine concentrations were observed
(four patients displayed a marked decrease in plasma carnitine concentrations, and
three other patients showed abnormalities in urinary excretion of carnitine).
Conclusions: These findings seem to suggest that a secondary carnitine deficiency,
induced by antiepileptic drugs (principally valproic acid), represents a plausible patho-
genetic mechanism for the development of dropped head in some epileptic patients.
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Noninflammatory myopathy, affecting predomi-
nantly the neck extensors, has been described by
Suarez and Kelly as a dropped head syndrome.1 It is
characterized by a gradual forward sagging of the
head due to the isolated weakness of the neck
extensor muscles. The syndrome has a relatively
benign clinical course, with the complaints having
a slowly progressive character in some of the sub-
jects. This condition may be difficult to distinguish
from more ominous neuromuscular disorders that
present with severe neck extensor weakness,
including myasthenia gravis, motor neuron disease,
and inflammatory axial myopathy. It could be asso-
ciated with a variety of pathologies, including spine
disorders, parkinsonism, dystonias, and hyperpar-
athyroidism.2—7 To date, there have been no reports
of dropped head syndrome in epileptic patients.Methods
Nine patients with intractable epilepsy (six males,
three females; ranged in age from 20 to 49 years,
with a mean age of 33.6  9.91 years), each pre-
senting with apparent dropped head syndrome,
were included in the study. Eight of the subjects
suffered from refractory multifocal epilepsy; the
remaining subject was diagnosed with an intract-
able progressive myoclonic epilepsy of unknown
etiology. All patients were mildly to severely men-
tally retarded, with IQ ranged from 34 to 70 (mean,
58.7  11.87) on the Wechsler Adult Intelligence
Scale (WAIS-R). Despite intensive pharmacological
polytherapy (combination of two to three antiepi-
leptic drugs) and therapeutic vagal nerve stimula-
tion (in four of the subjects), the seizure frequency
in our patients ranged from 4 to 85 seizures per
month (mean, 32.6  29.92). None of our patients
were taking neuroleptic drugs at the time of our
investigation, nor had they ever taken neuroleptic
drugs. The clinical features are summarized in
Table 1. The duration of the drooping head symptom
varied from 3 to 15 years (mean, 7.4  4.06 years),
and the weakness was slowly progressive in most of
the patients. In all of the patients, extensive clin-
ical, laboratory (including blood and urine tests for
L-carnitine, lactate, pyruvate, amino acids, and
organic acids), electrophysiological (polymyography
and EMG from the splenius capitis and sternoclei-
domastoid muscles), histopathological (biopsy spe-
cimens from the splenius capitis and vastus lateralis
muscles, including histochemical stains for NADH,
SDH, ATPase pH 9.4, pH 4.6, and pH 4.3, Oil-red-O,
Acid phosphatase, PAS, and Esterase), and neuroi-maging examinations (MRI or CT scans of the brain
and paraspinal muscles) were performed.Results
In all of the subjects, the weakness was strictly
limited to the cervical paraspinal muscles. No weak-
ness in other muscle groups, including in the
shoulder girdle region, was found. Due to the weak-
ness of the neck extensormuscles, our patients were
unable to hold the head upright, although on
request they could voluntarily and temporarily over-
come the problem and straighten the head up.
However, after a few seconds or minutes the gradual
forward sagging of the head could be observed. The
range of neck flexion varied roughly from 308 in the
milder cases to 608 in the most severe cases (Fig. 1).
The weakness did not fluctuate during the day.
Laboratory studies, including serum electrolytes
and creatine-kinase, produced normal results in
all subjects, and antibodies against acetylcholine
receptors were not detected. Thyroid function was
normal in most of the patients; in three of them,
slight, clinically non-significant changes were
found. EMG study and muscle biopsy were normal
or revealed subtle nonspecific myopathic changes
without inflammation in the cervical paraspinal
muscles. Electrophysiological and histopathological
examinations of control muscles revealed no
abnormities. Neither histological nor biochemical
findings suggestive of mitochondrial disorders were
observed. Polymyographic investigation revealed
that none of the patients had convincing dystonic
spasms of the anterior neck muscles. No atrophy or
fatty changes of the neck extensor muscles were
observed on CT or MRI. In one patient, slight sym-
metric edema-like changes in the neck muscles
were observed in a CT scan (pt. 6). In most of our
patients (7/9), altered L-carnitine concentrations
were observed (four patients displayed a marked
decrease in plasma carnitine concentrations, and
three patients showed abnormalities in urinary
excretion of the carnitine with normal plasma level
values) (Table 2). No obvious correlations between
the degree of carnitine deficiency and the neck
extensor weakness were revealed.Discussion
The nine patients with severe intractable epilepsies
and mental retardation reported in this study man-
ifested an unusual phenomenon of marked anterior
curvature of the cervical spine, designated as
dropped head syndrome. To the best of our knowl-
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Table 1 Patient characteristics.
Patient Sex Age
(years)
Type of epilepsy (etiology) Age of seizure
onset (years)
IQ Seizure
frequency
(/month)
Duration of drooping
head symptom (years)
Current medication VPA in
history
VNS
1 M 39 Intractable multifocal (perinatal injury) 0.5 58 85 4 (progressive) PRI (625 mg/d), TPM (400 mg/d),
LVT (3500 mg/d)
+ +
2 F 36 Intractable multifocal (postencephalitic) 3 50 12 3 (progressive) VPA (2000 mg/d), TPM (400 mg/d),
LVT (2000 mg/d)
+ +
3 F 28 Intractable multifocal (perinatal injury) 11 68 20 5 (nonprogressive) VPA (1500 mg/d), TPM (400 mg/d) + +
4 M 28 Intractable multifocal (LGS) 3 34 35 15 (nonprogressive) VPA (1500 mg/d), LTG (50 mg/d),
PRI (625 mg/d))
+ 
5 M 23 Intractable PME (unknown) 9 70 30 10 (nonprogressive) VPA (1500 mg/d), CZP (8 mg/d) + 
6 M 33 Intractable multifocal (perinatal injury?) 19 60 10 4 (progressive) VPA (2000 mg/d), LVT (750 mg/d) + +
7 M 49 Intractable multifocal (postencephalitic) 1.5 52 4 10 (progressive) LTG (400 mg/d), TGB (70 mg/d) + 
8 F 20 Intractable multifocal (perinatal injury?) 12 70 80 5 (progressive) PHT (250 mg/d), LTG (350 mg/d),
LVT (1000 mg/d)
+ 
9 M 46 Intractable multifocal (postencephalitic) 7 66 17 10 (nonprogressive) CBZ (900 mg/d), PHT (300 mg/d),
PRI (625 mg/d)
+ 
LGS: Lennox—Gastaut syndrome; PME: progressive myoclonic epilepsy; VNS: vagal nerve stimulation.
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Table 2 Summary of the laboratory findings seen in our patients.
Patient Paraspinal
muscle biopsy
Paraspinal
muscle EMG
Polymyography MRI/CT
scans
S-CK AchR
antibodies
Thyroid
function
U-creatinin S-carnitine U-carnitine
1 N N N N N N N N # Acylcarnitine " Acyl/unbound
carnitine ratio
2 MCM Low-amplitude
MUAPs
N N N N N N ## Total and
unbound carnitine
" Acyl/unbound
carnitine ratio
3 MCM N N N N N N N # Total and unbound
carnitine
Normal
4 N N N N N N N N # Total carnitine Normal
5 N N N N N N Slight #T3 N Normal " Acyl/unbound
carnitine ratio
6 MEF N N Symmetric
edema-like
changes
N N N N # Unbound carnitine " Acyl/unbound
carnitine ratio
7 MCM N N N N N N N Normal Normal
8 N N N N N N Slight #T4 N # Acylcarnitine "" Acyl/unbound
carnitine ratio
9 N N N N N N Slight #T3 N Normal Normal
MCM: minimal change myopathy; MEF: ‘‘moth-eaten’’ fibers; MUAPs: motor unit action potentials; S-CK: serum creatine-kinase; AchR: acetylcholine receptors.
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Figure 1 Examples of five epileptic patients demonstrating mild to severe neck extensor weakness with dropped head:
(a) patient 2; (b) patient 3; (c) patient 6; (d) patient 1; (e) patient 7 (with permission).edge, this is the first description of dropped head
syndrome in epileptic patients. The extensive exam-
ination of our patients obviously excluded known
neuromuscular disorders that present with severe
neck extensor weakness, including myasthenia
gravis, motor neuron disease, and inflammatory
axial myopathy. There were no clear-cut myopathic
changes in the EMG or histopathological studies on
the paraspinal muscles that would permit specula-
tion about idiopathic non-inflammatory axial myo-
pathy as the crucial pathogenetic mechanism of
development of dropped head syndrome in our
patients. Instead, in most of our patients, altera-
tions of L-carnitine concentrations were observed (a
significant decrease of the total and/or unbound
carnitine plasma levels in four subjects, and a sig-
nificant increase in urine acylcarnitine/unbound
carnitine ratio in an additional three subjects). L-
Carnitine, the active isoform of carnitine, is an
essential cofactor in the b-oxidation of fatty acids.
Its main function is transporting long-chain fatty
acids into the mitochondrial matrix for beta-oxida-
tion to provide cellular energy.8 The main conse-
quence of carnitine deficiency is an impaired energy
metabolism, which may be accompanied by a mod-
erate degree of muscular dysfunction (causing
weakness). Carnitine deficiency may be primary
or secondary, resulting from inborn errors of meta-
bolism, reduced dietary intake, medical conditions,
and treatment with multiple antiepileptic drugs,
including phenobarbital, phenytoin, carbamaze-
pine, and especially valproic acid.9,10 It is note-
worthy that five of our patients were taking high
doses of valproates at the time of the study, and all
of them had been medicated with valproate at some
point. Additionally, all subjects were medicated
with other antiepileptic drugs (AEDs), which demon-
strate the obvious potential to provoke secondarycarnitine deficiency. It is, therefore, not surprising
that carnitine deficiency (or abnormal urinary
carnitine excretion, possibly reflecting a higher
demand for carnitine in the organism) was observed
in a large portion of our subjects. The crucial point is
whether secondary carnitine deficiency truly can be
considered as the main pathogenetic factor in the
development of dropped head syndrome in epileptic
patients. Karpati et al. and VanDyke et al. described
weak neck muscles (extensors and flexors) and prox-
imal limbs as prominent features in carnitine defi-
ciency in young boys.9,11 In addition, carnitine
deficiency was repeatedly described as the cause
of camptocormia (bent spine syndrome), which is a
disorder characterized by extreme flexion of the
thoracolumbar spine. It has been suggested that
dropped head syndrome and camptocormia could
be viewed as two different manifestations of the
same axial myopathy.12 It is worth noting that camp-
tocormia was described in a mentally retarded 23-
year-old woman with myoclonic astatic epilepsy as
an obvious adverse effect of valproate monotherapy
by Kiuru and Iivanainen.13
It may be that dropped head syndrome in epilep-
tic patients does not represent a homogeneous
entity. We did not have abnormal carnitine meta-
bolism findings in all of our patients. However, the
crucial carnitine level in muscles does not necessa-
rily correspond to its plasma levels. A depletion of
carnitine level can occur in muscle tissue despite
normal serum and urine carnitine concentrations.
Unfortunately, for technical reasons we were unable
to verify the presumed carnitine deficiency in the
neck muscles of our patients. The pathogenesis of
dropped head in our cases thus remains hypotheti-
cal. It can be nevertheless suggested that a second-
ary carnitine deficiency induced by antiepileptic
drugs (principally by valproic acid) represents a
Dropped head syndrome in epilepsies patient 287plausible pathogenetic mechanism for the develop-
ment of dropped head syndrome in some epileptic
patients.
From a clinical point of view, it is very important
that the dropped head syndrome not be perceived
as a rarity throughout the epileptic community.
It can be overlooked and undiagnosed because
of its predominant occurrence in desperate
patients. The drooping head can nevertheless sig-
nificantly worsen the patients’ quality of life.
Further evaluations are needed to determine the
actual prevalence of dropped head syndrome in
patients with epilepsy, and whether drooping head
in these subjects is a consequence of intensive
antiepileptic drug treatment leading to secondary
carnitine deficiency. If this is the case, a replace-
ment of AEDs or carnitine supplementation should
be considered.14References
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